Cristian Alejandro Dimas-Ramírez, Luis André Fortanell-Meza, Diego San Agustín-Morales, Eduardo Brenner-Muslera, Juan Manuel Mejía-Vilet, Paloma Almeda-Valdes, Paola Vázquez-Cárdenas, Javier Merayo-Chalico, Ana Barrera-Vargas
{"title":"Steroid-induced diabetes in lupus nephritis patients: Classic risk factors or a different type of diabetes?","authors":"Cristian Alejandro Dimas-Ramírez, Luis André Fortanell-Meza, Diego San Agustín-Morales, Eduardo Brenner-Muslera, Juan Manuel Mejía-Vilet, Paloma Almeda-Valdes, Paola Vázquez-Cárdenas, Javier Merayo-Chalico, Ana Barrera-Vargas","doi":"10.1177/09612033251315976","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundGlucocorticoids are frequently employed in systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus nephritis (LN), despite their many side effects, including steroid-induced diabetes (SID). Information regarding SID in SLE patients is quite scant.PurposeThe aim of this study was to determine risk factors associated with the development of SID in patients with LN.Research Design A nested case-control study was conducted.Study sampleWe included patients with biopsy-proven LN, who received induction treatment with steroids.Data Collection and/or AnalysisOut of the total of 358 patients, 35 (9.7%) developed SID.ResultsPatients with SID had more metabolic risk factors, including the metabolic score for insulin resistance (METS-IR); more factors related with lupus activity, with higher SLEDAI and SLICC-DI scores; and lower cumulative pre-induction steroid dose. A higher percentage of patients who developed SID received steroid pulses and a lower percentage received antimalarials. After logistic regression, the variables significantly associated with the development of SID were the SLEDAI index (OR 1.25 [95% CI 1.04-1.50], <i>p</i> 0.01), SLICC-DI (OR 4.93 [95% CI 2.14-11.3], <i>p</i> < 0.001), METS-IR (OR 1.17 [95% CI 1.04-1.32], <i>p</i> 0.009), delta METS-IR at 6 months (OR 1.20 [95% CI 1.03-1.39], <i>p</i> 0.01), and the use of antimalarials (OR 0.14, [95% CI 0.02-0.85], <i>p</i> 0.03). After propensity score matching, METS-IR remained a significant predictor of SID. Patients with METS-IR >36.8 were at higher risk (OR: 2.83, 95% CI: 1.09-7.36, <i>p</i> = 0.034).ConclusionsIn conclusion, SDI development in patients receiving induction therapy for LN is associated with both classic metabolic risk factors and SLE-specific factors, and antimalarial use could be associated with a protective effect. Rheumatologists should be aware of this potential complication, in order to implement appropriate management strategies.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"234-242"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lupus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09612033251315976","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundGlucocorticoids are frequently employed in systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus nephritis (LN), despite their many side effects, including steroid-induced diabetes (SID). Information regarding SID in SLE patients is quite scant.PurposeThe aim of this study was to determine risk factors associated with the development of SID in patients with LN.Research Design A nested case-control study was conducted.Study sampleWe included patients with biopsy-proven LN, who received induction treatment with steroids.Data Collection and/or AnalysisOut of the total of 358 patients, 35 (9.7%) developed SID.ResultsPatients with SID had more metabolic risk factors, including the metabolic score for insulin resistance (METS-IR); more factors related with lupus activity, with higher SLEDAI and SLICC-DI scores; and lower cumulative pre-induction steroid dose. A higher percentage of patients who developed SID received steroid pulses and a lower percentage received antimalarials. After logistic regression, the variables significantly associated with the development of SID were the SLEDAI index (OR 1.25 [95% CI 1.04-1.50], p 0.01), SLICC-DI (OR 4.93 [95% CI 2.14-11.3], p < 0.001), METS-IR (OR 1.17 [95% CI 1.04-1.32], p 0.009), delta METS-IR at 6 months (OR 1.20 [95% CI 1.03-1.39], p 0.01), and the use of antimalarials (OR 0.14, [95% CI 0.02-0.85], p 0.03). After propensity score matching, METS-IR remained a significant predictor of SID. Patients with METS-IR >36.8 were at higher risk (OR: 2.83, 95% CI: 1.09-7.36, p = 0.034).ConclusionsIn conclusion, SDI development in patients receiving induction therapy for LN is associated with both classic metabolic risk factors and SLE-specific factors, and antimalarial use could be associated with a protective effect. Rheumatologists should be aware of this potential complication, in order to implement appropriate management strategies.
背景:糖皮质激素经常用于系统性红斑狼疮(SLE)患者,并在狼疮肾炎(LN)的诱导治疗中发挥关键作用,尽管它们有许多副作用,包括类固醇性糖尿病(SID)。关于SLE患者的SID的信息相当少。目的:本研究的目的是确定与LN患者发生SID相关的危险因素。研究设计:采用巢式病例对照研究。研究样本:我们纳入活检证实的LN患者,接受类固醇诱导治疗。数据收集和/或分析:在358例患者中,35例(9.7%)发生SID。结果:SID患者存在更多代谢危险因素,包括胰岛素抵抗代谢评分(METS-IR);与狼疮活动相关的因素较多,SLEDAI和SLICC-DI评分较高;更低的诱导前类固醇累积剂量。发生SID的患者接受类固醇脉冲治疗的比例较高,接受抗疟疾药物治疗的比例较低。logistic回归后,与SID发生显著相关的变量为SLEDAI指数(OR 1.25 [95% CI 1.04-1.50], p 0.01)、SLICC-DI (OR 4.93 [95% CI 2.14-11.3], p < 0.001)、METS-IR (OR 1.17 [95% CI 1.04-1.32], p 0.009)、6个月时delta METS-IR (OR 1.20 [95% CI 1.03-1.39], p 0.01)和抗疟药的使用(OR 0.14, [95% CI 0.02-0.85], p 0.03)。倾向评分匹配后,met - ir仍然是SID的显著预测因子。met - ir bb0 36.8的患者风险更高(OR: 2.83, 95% CI: 1.09-7.36, p = 0.034)。结论:综上所述,接受LN诱导治疗的患者的SDI发展与经典代谢危险因素和SDI特异性因素相关,抗疟药的使用可能具有保护作用。风湿病学家应该意识到这种潜在的并发症,以便实施适当的管理策略。
期刊介绍:
The only fully peer reviewed international journal devoted exclusively to lupus (and related disease) research. Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines. Invaluable reading, with extended coverage, lupus-related disciplines include: Rheumatology, Dermatology, Immunology, Obstetrics, Psychiatry and Cardiovascular Research…